Deletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane disease

Journal of Inflammation Research

Volumn 3, Issue 1, 2010, Pages 127-134

  Chafin, Cristen ^b   Muse, Sarah ^b   Hontecillas, Raquel ^e   Bassaganya Riera, Josep ^e   Caudell, David L ^c   Shimp, Samuel K ^d   Rylander, M Nichole ^d   Zhang, John ^f   Li, Liwu ^c   Reilly, Christopher M ^a,b  

^a EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^d Virginia Polytechnic Institute and State University   (United States)

^e VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antiglomerular basement membrane disease; Ppar

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 CD8 RATIO; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION; GENE TARGETING; GENETIC SUSCEPTIBILITY; GLOMERULONEPHRITIS; GLOMERULOPATHY; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEINURIA; REGULATORY T LYMPHOCYTE;

EID: 78650594606     PISSN: None     EISSN: 11787031     Source Type: Book Series    
DOI: 10.2147/JIR.S13394     Document Type: Article

References (42)

1. Abbate M, Kalluri R, Corna D, et al. Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with alpha3 chain of type IV collagen. Kidney Int. 1998;54:1550-1561.
2. Kettritz R. Autoimmunity in kidney diseases. Scand J Clin Lab Invest Suppl. 2008;241:99-103.
3. Bosch X, Font J. The pulmonary-renal syndrome: A poorly understood clinicopathologic condition. Lupus. 1999;8:258-262.
4. Du Y, Fu Y, Mohan C. Experimental anti-GBM nephritis as an analytical tool for studying spontaneous lupus nephritis. Arch Immunol Ther Exp (Warsz). 2008;56:31-40.
5. Xie C, Rahman ZS, Xie S, et al. Strain distribution pattern of immune nephritis - a follow-up study. Int Immunol. 2008;20:719-728.
6. Li QZ, Zhou J, Yang R, et al. The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis. Genes Immun. 2009;10:503-508.
7. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev. 1999;20:649-688.
8. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Oct 7, 2003. Circulation. 2003;108:2941-2948.
9. Yang M, Pariza MW, Cook ME. Dietary conjugated linoleic acid protects against end stage disease of systemic lupus erythematosus in the NZB/W F1 mouse. Immunopharmacol Immunotoxicol. 2000;22: 433-449.
10. Yang XY, Wang LH, Chen T, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem. 2000;275:4541-4544.
11. Bergamo P, Luongo D, Maurano F, Mazzarella G, Stefanile R, Rossi M. Conjugated linoleic acid enhances glutathione synthesis and attenuates pathological signs in MRL/MpJ-Fas(lpr) mice. J Lipid Res. 2006;47:2382-2391.
12. Venegas-Pont M, Sartori-Valinotti JC, Maric C, et al. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2009;296:R1282-R1289.
13. Aprahamian T, Bonegio RG, Richez C, et al. The peroxisome prolifer-ator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol. 2009;182:340-346.
14. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995;83:841-850.
15. Spiegelman BM. PPAR gamma in monocytes: Less pain, any gain? Cell. 1998;93:153-155.
16. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun. 1996;222:844-851.
17. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997;8:159-166.
18. Fajas L, Fruchart JC, Auwerx J. PPAR gamma3 mRNA: A distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett. 1998;438:55-60.
19. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinolog y. 1996;137:354-366.
20. Cui Y, Miyoshi K, Claudio E, et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem. 2002;277:17830-17835.
21. Adachi M, Kurotani R, Morimura K, et al. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut. 2006;55:1104-1113.
22. Guri AJ, Mohapatra SK, Horne WT 2nd, Hontecillas R, Bassaganya-Riera J. The role of T cell PPAR gamma in mice with experimental infammatory bowel disease. BMC Gastroenterol. 2010;10:60.
23. Mohapatra SK, Guri AJ, Climent M, et al. Immunoregulatory actions of epithelial cell PPAR gamma at the colonic mucosa of mice with experimental inflammatory bowel disease. PLoS One. 2010;5:e10215.
24. Akiyama TE, Sakai S, Lambert G, et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol. 2002;22:2607-2619.
25. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental infammatory bowel disease. Gastroenterology. 2004;127:777-791.
26. Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol. 2007;178:2940-2949.
27. Guri AJ, Hontecillas R, Ferrer G, et al. Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. J Nutr Biochem. 2008;19:216-228.
28. Evans N P, Misyak SA, Schmelz EM, Guri AJ, Hontecillas R, Bassaganya-Riera J. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma. J Nutr. 2010;140:515-521.
29. Ahmed SA, Gogal RM Jr, Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: An alternative to [3H]thymidine incorporation assay. J Immunol Methods. 1994;170:211-224.
30. Sekine H, Reilly CM, Molano ID, et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol. 2001;166:6444-6451.
31. Xie C, Sharma R, Wang H, Zhou XJ, Mohan C. Strain distribution pattern of susceptibility to immune-mediated nephritis. J Immunol. 2004;172:5047-5055.
32. Malur A, McCoy AJ, Arce S, et al. Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary infammatory response. J Immunol. 2009;182:5816-5822.
33. Wohlfert EA, Nichols FC, Nevius E, Clark RB. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: Enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol. 2007;178:4129-4135.
34. Lavinsky RM, Jepsen K, Heinzel T, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998;95:2920-2925.
35. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998;95:7614-7619.
36. Fu Y, Du Y, Mohan C. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin Immunol. 2007;124: 109-118.
37. Reilly CM, Thomas M, Gogal R Jr, et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J Autoimmun. 2008;31: 123-130.
38. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res. 2005;65:772-781.
39. Wan S, Xia C, Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J Immunol. 2007;178:271-279.
40. Reilly CM, Oates JC, Cook JA, Morrow JD, Halushka P V, Gilkeson GS. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by pros-taglandin J(2) and proliferator activation receptor-gamma agonists. J Immunol. 2000;164:1498-1504.
41. Namgaladze D, Morbitzer D, von Knethen A, Brune B. Phospholipase A2-modifed low-density lipoprotein activates macrophage peroxi-some proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010;30:313-320.
42. Borniquel S, Jansson EA, Cole M P, Freeman BA, Lundberg JO. Nitrated oleic acid up-regulates PPARgamma and attenuates experimental infammatory bowel disease. Free Radic Biol Med. 2010;48: 499-505.